Cargando…

An Observational Study Assessing Changes in Health and Functional Status in Patients with Chronic Obstructive Pulmonary Disease (COPD) During Therapy with Spiolto(®) Respimat(®) in Everyday Clinical Practice: The Greek ELLACTO Study

INTRODUCTION: Patients with chronic obstructive pulmonary disease (COPD) often report deteriorated functional status and poor health-related quality of life, both core aspects of their overall health status. The study objective was to assess tiotropium/olodaterol Respimat(®) effects on health and fu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kosmas, Epaminondas, Titopoulos, Iraklis, Patentalakis, Georgios, Nikas, Nikos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589918/ https://www.ncbi.nlm.nih.gov/pubmed/33939158 http://dx.doi.org/10.1007/s41030-021-00156-7

Ejemplares similares

Assessment of Patient Experiences with Respimat(®) in Everyday Clinical Practice
por: Taube, Christian, et al.
Publicado: (2020)

Prevalence of alexithymia and its association with anxiety and depression in a sample of Greek chronic obstructive pulmonary disease (COPD) outpatients
por: Tselebis, Athanasios, et al.
Publicado: (2010)

Use of Respimat(®) Soft Mist™ Inhaler in COPD patients
por: Anderson, Paula
Publicado: (2006)

Efficacy and safety of tiotropium Respimat(®) SMI in COPD in two 1-year randomized studies
por: Bateman, Eric, et al.
Publicado: (2010)

Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis
por: Halpin, David MG, et al.
Publicado: (2015)

Bronchodilator Effect of Tiotropium via Respimat(Ⓡ) Administered with a Spacer in Patients with Chronic Obstructive Pulmonary Disease (COPD)
por: Ogasawara, Takashi, et al.
Publicado: (2017)

COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study
por: Ferguson, Gary T, et al.
Publicado: (2013)

Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease
por: Rau-Berger, Heike, et al.
Publicado: (2010)

In vitro dose comparison of Respimat(®) inhaler with dry powder inhalers for COPD maintenance therapy
por: Ciciliani, Anna-Maria, et al.
Publicado: (2017)

Greek Guidelines for the Management of COPD, a Proposal of a Holistic Approach Based on the needs of the Greek Community
por: Tzanakis, Nikolaos, et al.
Publicado: (2022)

Lack of paradoxical bronchoconstriction after administration of tiotropium via Respimat(®) Soft Mist™ Inhaler in COPD
por: Hodder, Rick, et al.
Publicado: (2011)

The Cultural Adaptation of the Everyday Problems Test—Greek Version: An Instrument to Examine Everyday Functioning
por: Pavlidis, George, et al.
Publicado: (2021)

Long-term safety of tiotropium/olodaterol Respimat(®) in patients with moderate-to-very severe COPD and renal impairment in the TONADO(®) studies
por: LaForce, Craig, et al.
Publicado: (2018)

A dose-ranging study of tiotropium delivered via Respimat(®) Soft Mist(TM) Inhaler or HandiHaler(®) in COPD patients
por: Caillaud, Denis, et al.
Publicado: (2007)

Strategies to improve anxiety and depression in patients with COPD: a mental health perspective
por: Tselebis, Athanasios, et al.
Publicado: (2016)

Higher lung deposition with Respimat(®) Soft Mist(™) Inhaler than HFA-MDI in COPD patients with poor technique
por: Brand, Peter, et al.
Publicado: (2008)

Assessment of physical functioning and handling of tiotropium/olodaterol Respimat(®) in patients with COPD in a real-world clinical setting
por: Steinmetz, Karl-Otto, et al.
Publicado: (2019)

The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies
por: Ichinose, Masakazu, et al.
Publicado: (2016)

Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat(®) Soft Mist(™) Inhaler
por: Hodder, Richard, et al.
Publicado: (2009)

Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies
por: ZuWallack, Richard, et al.
Publicado: (2014)

Tiotropium respimat(®) add-on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of T(H)2 inflammatory status
por: Yang, WH, et al.
Publicado: (2014)

Asthma patients prefer Respimat(®) Soft Mist™ Inhaler to Turbuhaler(®)
por: Hodder, Rick, et al.
Publicado: (2009)

The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes
por: Anzueto, Antonio, et al.
Publicado: (2015)

Efficacy and safety of olodaterol once daily delivered via Respimat(®) in patients with GOLD 2–4 COPD: results from two replicate 48-week studies
por: Ferguson, Gary T, et al.
Publicado: (2014)

Patient perceptions of the re-usable Respimat(®) Soft Mist™ inhaler in current users and those switching to the device: A real-world, non-interventional COPD study
por: Dreher, Michael, et al.
Publicado: (2021)

Physical Functioning in Patients with Chronic Obstructive Pulmonary Disease Treated with Tiotropium/Olodaterol Respimat in Routine Clinical Practice in Italy
por: Carone, Mauro, et al.
Publicado: (2020)

Determinants of frailty in primary care patients with COPD: the Greek UNLOCK study
por: Ierodiakonou, Despo, et al.
Publicado: (2019)

Dual Bronchodilator in the Era of Triple Therapy
por: Papaioannou, Andriana I, et al.
Publicado: (2020)

A Real-World Observational Study Examining the Impact of Aclidinium Bromide Therapy on the Quality of Life, Symptoms, and Activity Impairment of Patients with Chronic Obstructive Pulmonary Disease: The Greek ON-AIR Study
por: Kostikas, Konstantinos, et al.
Publicado: (2020)

Risk factors influencing the prescription of tiotropium Respimat formulation: a population-based cohort study
por: Trotta, Francesco, et al.
Publicado: (2015)

Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat(®) device for maintenance treatment of COPD: comparison with the long-acting β(2)-agonist formoterol
por: Koch, Andrea, et al.
Publicado: (2017)

Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®)
por: Dekhuijzen, Pieter Nicolaas Richard, et al.
Publicado: (2016)

The Respimat(®) Soft Mist Inhaler: Implications of Drug Delivery Characteristics for Patients
por: Iwanaga, Takashi, et al.
Publicado: (2019)

Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat(®) Inhaler in Patients with Chronic Obstructive Pulmonary Disease
por: Aalbers, René, et al.
Publicado: (2015)

A systematic review of comparative studies of tiotropium Respimat® and tiotropium HandiHaler® in patients with chronic obstructive pulmonary disease: does inhaler choice matter?
por: Dahl, Ronald, et al.
Publicado: (2016)

COPD from an everyday primary care point of view
por: Aguilar-Shea, Antonio L., et al.
Publicado: (2019)

A pulmonary rehabilitation program reduces levels of anxiety and depression in COPD patients
por: Tselebis, Athanasios, et al.
Publicado: (2013)

COPD patients’ characteristics, usual care, and adherence to guidelines: the Greek UNLOCK study
por: Tsiligianni, Ioanna, et al.
Publicado: (2019)

The pharmacological cost of COPD during Greek economic crisis
por: Stafyla, Eirini, et al.
Publicado: (2017)

Sestrin 2 levels are associated with emphysematous phenotype of COPD
por: Angelakis, Leonidas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ehd374fb3ps7se10mjegrs1vja